Margaret G. Mcglynn - Mar 31, 2022 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
Director
Signature
/s/ Sabrina Yohai, Attorney-in-Fact
Stock symbol
VRTX
Transactions as of
Mar 31, 2022
Transactions value $
-$1,311,346
Form type
4
Date filed
4/4/2022, 04:05 PM
Previous filing
Feb 1, 2022
Next filing
Apr 12, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Options Exercise $638 K +5 K +454.96% $127.54 6.1 K Mar 31, 2022 Direct
transaction VRTX Common Stock Sale -$266 K -1.02 K -16.71% $261.28 5.08 K Mar 31, 2022 Direct F1, F2, F3
transaction VRTX Common Stock Sale -$779 K -2.97 K -58.46% $262.37 2.11 K Mar 31, 2022 Direct F1, F3, F4
transaction VRTX Common Stock Sale -$266 K -1.01 K -47.91% $262.97 1.1 K Mar 31, 2022 Direct F1, F3, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VRTX Common Stock (right to buy) Options Exercise -$638 K -5 K -33.33% $127.54 10 K Mar 31, 2022 Common Stock 5 K $127.54 Direct F6

Explanation of Responses:

Id Content
F1 Transaction made pursuant to Ms. McGlynn's company approved trading plan under Rule 10b5-1.
F2 Open market sales reported on this line occurred at a weighted average price of $261.28 (range $260.78 to $261.73).
F3 Ms. McGlynn undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F4 Open market sales reported on this line occurred at a weighted average price of $262.37 (range $261.79 to $262.78).
F5 Open market sales reported on this line occurred at a weighted average price of $262.97 (range $262.80 to $263.34).
F6 Fully vested